Jump to content

Marquette hospital seeks lung cancer patients for nationwide

Recommended Posts


Published Wednesday, January 10, 2007 4:47:33 PM Central Time

MARQUETTE -- The Marquette General Cancer Center is participating in a nationwide clinical trial to test a new drug in lung cancer.

The ATLAS study will focus on lung cancer patients whose tumors cannot be treated with radiation or surgery.

Patients who may be eligible for enrollment in the trial are those with "locally advanced, recurrent, or metastatic, non-small cell" lung cancer.

Marquette General is the only institution in Upper Michigan and northeastern Wisconsin to make this clinical trial available to local patients.

Eligible patients will receive four cycles of chemotherapy and bevacizumab. After four cycles, participants who do not have disease progression will be randomly sorted into either a bevacizumab plus erlotinib or bevacizumab plus placebo group.

It is estimated that approximately 1,200 patients nationwide will be appropriate for the trial, and Marquette General is seeking to enroll a minimum of 10 patients.

To enroll in this trial, patients must be referred to one of the medical oncologists at Marquette General Hospital.

For more information, contact the Marquette General Cancer Center research department at (906) 225-3467, or (800) 562-9753, extension 3467, or visit the Marquette General Web site at mgh.org/cancer

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use. We have placed cookies on your device to help make this website better. You can adjust your cookie settings, otherwise we'll assume you're okay to continue.